(NASDAQ: LXRX) Lexicon Pharmaceuticals's forecast annual revenue growth rate of 18.53% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 28.18%, and while it is forecast to beat the US market's average forecast revenue growth rate of 12.17%.
Lexicon Pharmaceuticals's revenue in 2026 is $38,537,000.On average, 8 Wall Street analysts forecast LXRX's revenue for 2026 to be $16,821,407,327, with the lowest LXRX revenue forecast at $13,875,290,171, and the highest LXRX revenue forecast at $20,663,336,440. On average, 8 Wall Street analysts forecast LXRX's revenue for 2027 to be $8,111,283,414, with the lowest LXRX revenue forecast at $0, and the highest LXRX revenue forecast at $29,966,512,801.
In 2028, LXRX is forecast to generate $34,402,830,067 in revenue, with the lowest revenue forecast at $2,617,979,277 and the highest revenue forecast at $69,563,449,373.